NO20042779L - Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger - Google Patents

Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger

Info

Publication number
NO20042779L
NO20042779L NO20042779A NO20042779A NO20042779L NO 20042779 L NO20042779 L NO 20042779L NO 20042779 A NO20042779 A NO 20042779A NO 20042779 A NO20042779 A NO 20042779A NO 20042779 L NO20042779 L NO 20042779L
Authority
NO
Norway
Prior art keywords
agonist
partial
pharmaceutical compositions
containing pharmaceutical
compositions
Prior art date
Application number
NO20042779A
Other languages
English (en)
Inventor
Jerome Aubert
Vitzing Christian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20042779L publication Critical patent/NO20042779L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20042779A 2001-12-21 2004-07-01 Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger NO20042779L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod
PCT/EP2002/014674 WO2003053432A1 (en) 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO20042779L true NO20042779L (no) 2004-09-17

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042779A NO20042779L (no) 2001-12-21 2004-07-01 Partiell 5HT4-agonistholdige farmsaoytiske sammensetninger

Country Status (31)

Country Link
US (2) US20050106236A1 (no)
EP (2) EP1321142A1 (no)
JP (1) JP4718776B2 (no)
KR (1) KR100980144B1 (no)
CN (1) CN100464749C (no)
AR (1) AR037937A1 (no)
AT (1) ATE320807T1 (no)
AU (1) AU2002361198B2 (no)
BR (1) BR0215148A (no)
CA (1) CA2470668C (no)
CO (1) CO5640102A2 (no)
CY (1) CY1105559T1 (no)
DE (1) DE60210139T2 (no)
DK (1) DK1458377T3 (no)
EC (1) ECSP105163A (no)
EG (1) EG24194A (no)
ES (1) ES2258171T3 (no)
HU (1) HU226589B1 (no)
IL (2) IL162451A0 (no)
MX (1) MXPA04006157A (no)
MY (1) MY139546A (no)
NO (1) NO20042779L (no)
NZ (1) NZ533585A (no)
PE (1) PE20030872A1 (no)
PL (1) PL369509A1 (no)
PT (1) PT1458377E (no)
RU (1) RU2322978C2 (no)
SI (1) SI1458377T1 (no)
TW (1) TWI260221B (no)
WO (1) WO2003053432A1 (no)
ZA (1) ZA200404467B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257869T3 (es) * 1998-08-21 2006-08-01 Novartis Ag Nueva formulacion oral para agonistas o antagonistas de 5-ht4.
ATE477268T1 (de) 2003-01-28 2010-08-15 Ironwood Pharmaceuticals Inc Zusammensetzungen zur behandlung von magen-darm- störungen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2003222439A1 (en) * 2003-03-25 2004-10-18 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
US20070065801A1 (en) * 2003-05-21 2007-03-22 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (seotonin) receptor 4 (5-ht4)
MY137386A (en) * 2003-07-24 2009-01-30 Novartis Ag Stable modifications of tegaserod hydrogen maleate
ES2401769T5 (es) 2003-09-12 2020-07-01 Amgen Inc Formulación de disolución rápida de cinacalcet HCl
JP2007514000A (ja) * 2003-12-16 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド テガセロッド塩基及びその塩の多形現象形
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX2009013293A (es) 2007-06-04 2010-02-15 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos.
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
KR20170091783A (ko) 2008-12-31 2017-08-09 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2013304812B2 (en) 2012-08-21 2016-06-09 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
SMT201900386T1 (it) 2013-04-12 2019-09-09 Ardelyx Inc Composti nhe3-leganti e metodi per l'inibizione del trasporto di fosfato
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬
AU2018205400C1 (en) 2017-01-09 2026-01-15 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
ES2257869T3 (es) * 1998-08-21 2006-08-01 Novartis Ag Nueva formulacion oral para agonistas o antagonistas de 5-ht4.
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
NZ516616A (en) * 1999-08-03 2003-07-25 Lilly Icos Llc Beta-carboline pharmaceutical compositions

Also Published As

Publication number Publication date
BR0215148A (pt) 2004-10-19
KR20040066922A (ko) 2004-07-27
AR037937A1 (es) 2004-12-22
DK1458377T3 (da) 2006-06-12
PT1458377E (pt) 2006-07-31
HUP0402492A2 (hu) 2005-07-28
TW200410684A (en) 2004-07-01
PE20030872A1 (es) 2003-11-24
PL369509A1 (en) 2005-04-18
CN100464749C (zh) 2009-03-04
EG24194A (en) 2008-10-14
IL162451A0 (en) 2005-11-20
DE60210139D1 (de) 2006-05-11
RU2004122631A (ru) 2005-08-10
MXPA04006157A (es) 2004-10-27
MY139546A (en) 2009-10-30
CN1606438A (zh) 2005-04-13
ATE320807T1 (de) 2006-04-15
SI1458377T1 (sl) 2006-08-31
AU2002361198A1 (en) 2003-07-09
KR100980144B1 (ko) 2010-09-03
HU226589B1 (en) 2009-04-28
NZ533585A (en) 2006-04-28
RU2322978C2 (ru) 2008-04-27
WO2003053432A1 (en) 2003-07-03
ECSP105163A (es) 2010-07-30
JP2005516946A (ja) 2005-06-09
CA2470668C (en) 2011-07-05
EP1458377B1 (en) 2006-03-22
EP1458377A1 (en) 2004-09-22
US20090104263A1 (en) 2009-04-23
CY1105559T1 (el) 2010-07-28
AU2002361198B2 (en) 2006-06-08
CA2470668A1 (en) 2003-07-03
ES2258171T3 (es) 2006-08-16
JP4718776B2 (ja) 2011-07-06
CO5640102A2 (es) 2006-05-31
EP1321142A1 (en) 2003-06-25
ZA200404467B (en) 2006-05-31
HUP0402492A3 (en) 2008-04-28
US20050106236A1 (en) 2005-05-19
TWI260221B (en) 2006-08-21
DE60210139T2 (de) 2006-08-17
IL162451A (en) 2009-02-11

Similar Documents

Publication Publication Date Title
FI20011478A0 (fi) Farmaseuttinen koostumus
FI20010780A0 (fi) Parannetut koostumukset
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
PL367180A1 (pl) Trwała kompozycja farmaceutyczna
EE200300416A (et) Ravimvorm
ITMI20010748A0 (it) Composizioni farmaceutiche
GB0111597D0 (en) Pharmaceutical compositions
NO20052306D0 (no) Dispergerbare farmasoytiske blandinger.
IL162451A0 (en) 5Ht4 partial agonist pharmaceutical compositions
BR0210619A (pt) composição
IS7051A (is) Lyfjasamsetningar
IS7081A (is) Lyfjablanda
FI20022128A7 (fi) Farmaseuttinen koostumus
NO20026123L (no) Farmasöytiske sammensetninger
EP1461096A4 (en) ROTATING COMPRESSOR
NO20031095D0 (no) Farmasöytiske sammensetninger
GB0104752D0 (en) Pharmaceutical compositions
ITTO20020744A0 (it) Composizione
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
DE60140529D1 (de) Feuerlöschende Zusammensetzung
ITTO20020745A0 (it) Composizione
EE200200689A (et) Ravimkoostised
NO20015694D0 (no) Emballasje

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application